MeSH D014571 - urologic neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Astellas Pharma | Enfortumab vedotin | Padcev |  | 2022-04-13 |  |  |
| Bristol Myers Squibb | Nivolumab | Opdivo |  | 2015-06-19 | $9,212 M | Q4/23-Q3/24 |
| Laboratoires Pierre Fabre | Vinflunine | Javlor |  | 2009-09-21 |  |  |
| Merck & Co | Pembrolizumab | Keytruda |  | 2015-07-17 | $28,253 M | Q4/23-Q3/24 |
| Roche | Atezolizumab | Tecentriq |  | 2017-09-20 | $4,406.336 M | Q4/22-Q3/23 |
Clinical Trials
Historical Success Rate
Phase 1
66%57/87
Phase 2
19%20/103
Phase 3
36%9/25
Approved: 6Overall Success rate: 5%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use